Insight on Pharmaceutical Manufacturers

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Click here to sort results by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Dendreon Corporation: PharmaVitae Report

This report analyzes Dendreon's corporate strategy and sales outlook through to 2016, supported by in-depth analysis of the company’s key products and pipeline, driven by patient-based forecasts and key opinion leader interviews.

Published By Datamonitor
27 Jan 2012 $2800
Buy
Report
Report

Eli Lilly & Co.: PharmaVitae Report

Analysis of Eli Lilly's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
24 Jun 2011 $2800
Buy
Report
Report

F. Hoffmann-La Roche Ltd: PharmaVitae Report

Analysis of Roche's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
06 Jun 2011 $2800
Buy
Report
Report

Genzyme Corporation: PharmaVitae Report

Analysis of Genzyme's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
06 May 2011 $2800
Buy
Report
Report

GlaxoSmithKline plc: Company Analysis

Analysis of GlaxoSmithKline's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $2800
Buy
Report
Report

Intas: Biosimilars Company Analysis

Analysis of Intas’s corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.

Published By Datamonitor
24 Jul 2012 $2800
Buy
Report
Report

Ironwood Pharmaceuticals: Company Analysis

Analysis of Ironwood Pharmaceuticals' corporate history, corporate relationships, prospects to the end of the forecast period, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.

Published By Datamonitor
09 Oct 2012 $2800
Buy
Case Studies
Case Studies

Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster

Remicade is a biotechnology-based drug for immune system diseases. It is the best-selling "biologic" in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.

Published By MarketLine
02 Dec 2011 $495
Buy
Report
Report

Johnson & Johnson: PharmaVitae Report

Analysis of Johnson & Johnson's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
30 Jun 2011 $2800
Buy
Case Studies
Case Studies

Johnson & Johnson: Product recalls in the OTC pharmaceuticals business

Johnson & Johnson is the largest manufacturer of over-the-counter (OTC) healthcare products in the US. However, this position has been threatened in recent years by a number of manufacturing issues that have led to a series of product recalls.

Published By MarketLine
28 Jan 2013 $495
Buy

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.